Blog

- DISEASE ADVANCES

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

OSLO, Norway, March 3, 2026 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from China’s National Medical Products Administration (NMPA), enabling commercial launch in China.

Read More »

SciBase receives approval by FDA for extended labelling in the US

STOCKHOLM, March 2, 2026 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure

Read More »